CA3056570C - Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders - Google Patents

Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders Download PDF

Info

Publication number
CA3056570C
CA3056570C CA3056570A CA3056570A CA3056570C CA 3056570 C CA3056570 C CA 3056570C CA 3056570 A CA3056570 A CA 3056570A CA 3056570 A CA3056570 A CA 3056570A CA 3056570 C CA3056570 C CA 3056570C
Authority
CA
Canada
Prior art keywords
calcium
acc
bone
subjects
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3056570A
Other languages
English (en)
French (fr)
Other versions
CA3056570A1 (en
Inventor
Amir Sagi
Assaf Shechter
Galit SHALTIEL-GOLD
Michal Daniely
Oren MEIRON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorphical Ltd
Original Assignee
Amorphical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorphical Ltd filed Critical Amorphical Ltd
Publication of CA3056570A1 publication Critical patent/CA3056570A1/en
Application granted granted Critical
Publication of CA3056570C publication Critical patent/CA3056570C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3056570A 2011-12-13 2012-12-13 Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders Active CA3056570C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161569805P 2011-12-13 2011-12-13
US61/569,805 2011-12-13
US201261680721P 2012-08-08 2012-08-08
US61/680,721 2012-08-08
CA2859122A CA2859122C (en) 2011-12-13 2012-12-13 Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2859122A Division CA2859122C (en) 2011-12-13 2012-12-13 Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders

Publications (2)

Publication Number Publication Date
CA3056570A1 CA3056570A1 (en) 2013-06-20
CA3056570C true CA3056570C (en) 2022-04-19

Family

ID=48611949

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3056570A Active CA3056570C (en) 2011-12-13 2012-12-13 Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders
CA2859122A Active CA2859122C (en) 2011-12-13 2012-12-13 Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2859122A Active CA2859122C (en) 2011-12-13 2012-12-13 Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders

Country Status (10)

Country Link
US (2) US10064890B2 (cg-RX-API-DMAC10.html)
EP (1) EP2790710B1 (cg-RX-API-DMAC10.html)
JP (3) JP2015500333A (cg-RX-API-DMAC10.html)
CN (2) CN104114179A (cg-RX-API-DMAC10.html)
AU (3) AU2012354056B2 (cg-RX-API-DMAC10.html)
CA (2) CA3056570C (cg-RX-API-DMAC10.html)
DK (1) DK2790710T3 (cg-RX-API-DMAC10.html)
ES (1) ES2831699T3 (cg-RX-API-DMAC10.html)
IL (2) IL233107B (cg-RX-API-DMAC10.html)
WO (1) WO2013088440A1 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150374747A1 (en) * 2013-02-11 2015-12-31 Amorphical Ltd. Amorphous calcium carbonate for accelerated bone growth
CA2956048C (en) 2014-07-31 2023-01-24 Amorphical Ltd. Encapsulated amorphous calcium carbonate compositions
US12121538B2 (en) 2015-06-04 2024-10-22 Amorphical Ltd. Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration
AU2016273058B2 (en) * 2015-06-04 2021-05-20 Amorphical Ltd. Amorphous calcium carbonate stabilized with polyphosphates or bisphosphonates
JP2017032550A (ja) * 2015-07-30 2017-02-09 大塚製薬株式会社 胃粘膜萎縮の有無を判定する方法
US12629390B2 (en) 2016-01-18 2026-05-19 Amorphical Ltd. Stabilized amorphous calcium carbonate for treatment of neurological, muscular and infertility diseases or conditions
AU2017210259B2 (en) 2016-01-18 2022-11-03 Amorphical Ltd. Stabilized amorphous calcium carbonate as a supplement for cell culture media
US20230365935A1 (en) * 2016-01-18 2023-11-16 Amorphical Ltd. Stabilized amorphous calcium carbonate as a supplement for cell culture media
KR102828392B1 (ko) 2016-01-18 2025-07-02 아모피컬 리미티드 신경, 근육 및 불임 질환 또는 병증의 치료를 위한 안정화된 무정형 탄산칼슘
JP6872680B2 (ja) * 2016-03-22 2021-05-19 国立大学法人 宮崎大学 カルシウム吸収促進剤
IL266149B (en) * 2016-10-25 2022-08-01 Amorphical Ltd Amorphous calcium carbonate for treating a leukemia
CN110123836A (zh) * 2019-05-20 2019-08-16 昆明朗盛生物科技有限公司 钙锌维生素d泛酸片的应用
MX2022000947A (es) 2019-07-23 2022-04-26 Amorphical Ltd Carbonato de calcio amorfo para mejorar el rendimiento deportivo.
BR112022018055A2 (pt) * 2020-03-11 2022-10-18 Amorphical Ltd Carbonato de cálcio amorfo para tratamento de acidose.
WO2021226064A1 (en) * 2020-05-04 2021-11-11 University Of Louisville Research Foundation, Inc. Artificial intelligence-based systems and methods for dosing of pharmacologic agents
MX2023002801A (es) * 2020-09-15 2023-04-21 Oncoinvent As Particulas radiomarcadas de tama?o controlado.
JP7573310B2 (ja) * 2022-02-28 2024-10-25 一般社団法人 Unical ヒトによる経口摂取のためのカルシウム組成物
AU2023378960A1 (en) * 2022-11-08 2025-06-12 Amorphical Ltd. Methods for preparing amorphous calcium carbonate by fixation of carbon dioxide
WO2026044304A1 (en) * 2024-08-20 2026-02-26 Clarke Black Kim Jean A health supplement composition, and a method of manufacturing a health supplement composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304987B1 (en) * 1987-08-28 1992-11-11 Norwich Eaton Pharmaceuticals, Inc. Novel calcium supplements
CA1336328C (en) 1988-04-11 1995-07-18 Walter G. Leonard Method of increasing bone density in humans
WO1997024069A1 (en) 1995-12-26 1997-07-10 Holomed Aps A method and system for generating an x-ray image
JPH10236957A (ja) 1997-02-24 1998-09-08 Bankaku Souhonpo:Kk 骨粗鬆症の改善剤
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
JP2003292453A (ja) 2002-04-02 2003-10-15 Asahi Kasei Corp 骨疾患治療用医薬複合剤
US7267832B2 (en) * 2004-02-18 2007-09-11 Kraft Foods Holdings, Inc. Amorphous water-soluble calcium citrate salts and method of making and using same
ES2447747T3 (es) * 2004-05-26 2014-03-12 Ben Gurion University Of The Negev Research And Development Authority Composiciones administrables por vía oral que comprenden carbonato cálcico amorfo estable
US20070041506A1 (en) 2005-08-22 2007-02-22 Michelle Bottino Digital sensor holder
GB0522045D0 (en) 2005-10-28 2005-12-07 Novartis Ag Pharmaceutical compositions
IL178495A (en) * 2006-10-05 2014-12-31 Univ Ben Gurion Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions
US8802160B2 (en) * 2007-10-22 2014-08-12 Amorphical Ltd. Stable amorphous calcium carbonate comprising phosphorylated amino acids
WO2009087553A1 (en) 2008-01-02 2009-07-16 Aurobindo Pharma Limited Kits for administering bisphosphonates
CN101314031A (zh) 2008-07-14 2008-12-03 王冰 一种改善骨营养的制剂
WO2010045558A1 (en) * 2008-10-17 2010-04-22 Fresenius Medical Care Holdings, Inc. Method of determining a phosphorus binder dosage for a dialysis patient
CN102085356B (zh) 2010-12-28 2013-02-27 北京同仁堂健康药业股份有限公司 一种用于增加骨密度的组合物及其制备方法

Also Published As

Publication number Publication date
AU2017279824A1 (en) 2018-01-25
JP2018138591A (ja) 2018-09-06
IL233107B (en) 2020-06-30
AU2012354056A1 (en) 2014-07-10
EP2790710A1 (en) 2014-10-22
IL274755A (en) 2020-07-30
US20150056306A1 (en) 2015-02-26
AU2020200704A1 (en) 2020-02-20
US10064890B2 (en) 2018-09-04
JP2019214631A (ja) 2019-12-19
JP2015500333A (ja) 2015-01-05
CA2859122C (en) 2019-11-05
DK2790710T3 (da) 2020-11-30
CA2859122A1 (en) 2013-06-20
US10688124B2 (en) 2020-06-23
AU2012354056B2 (en) 2017-10-05
EP2790710B1 (en) 2020-08-26
AU2012354056A8 (en) 2017-10-12
IL274755B (en) 2021-04-29
ES2831699T3 (es) 2021-06-09
WO2013088440A1 (en) 2013-06-20
US20190022133A1 (en) 2019-01-24
EP2790710A4 (en) 2015-11-11
CN104114179A (zh) 2014-10-22
WO2013088440A8 (en) 2013-08-01
CA3056570A1 (en) 2013-06-20
CN109568338A (zh) 2019-04-05
IL233107A0 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
US10688124B2 (en) Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders
Wada et al. NPS R-568 halts or reverses osteitis fibrosa in uremic rats
US20100144679A1 (en) Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
JP6301524B2 (ja) 骨粗鬆症治療剤ないし予防剤
US11026906B2 (en) Pharmaceutical quality strontium L-lactate
Iwamoto et al. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis
Akcay et al. Alendronate treatment in children with osteogenesis imperfecta
TW200412979A (en) Method for preventing or reducing secondary fractures after hip fracture
Reginster et al. Strontium ranelate: a new paradigm in the treatment of osteoporosis
TWI590829B (zh) 口服ｂ１２的療法
Nordborg et al. The ineffectiveness of cyclical oral clodronate on bone mineral density in glucocorticoid‐treated patients with giant‐cell arteritis
Regulator et al. Pr MYLAN-ETI-CAL CAREPAC
CN1248168A (zh) 9,10－断胆甾－5,7,10(19)－三烯－1,3－二醇或1α－羟维生素D3的用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190924

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241204

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241204

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241204

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251201

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251201